Cite
HARVARD Citation
Redfield, R. et al. (2019). Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American journal of transplantation. 19 (11), pp. 3035-3045. [Online].